Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine
dc.contributor.author | Shihab, Fuad S. | en_US |
dc.contributor.author | Cibrik, Diane | en_US |
dc.contributor.author | Chan, Laurence | en_US |
dc.contributor.author | Kim, Yu Seun | en_US |
dc.contributor.author | Carmellini, Mario | en_US |
dc.contributor.author | Walker, Rowan | en_US |
dc.contributor.author | Zibari, Gazi | en_US |
dc.contributor.author | Pattison, James | en_US |
dc.contributor.author | Cornu‐artis, Catherine | en_US |
dc.contributor.author | Wang, Zailong | en_US |
dc.contributor.author | Tedesco‐silva Jr, Helio | en_US |
dc.date.accessioned | 2013-05-02T19:35:10Z | |
dc.date.available | 2014-05-01T14:28:32Z | en_US |
dc.date.issued | 2013-03 | en_US |
dc.identifier.citation | Shihab, Fuad S.; Cibrik, Diane; Chan, Laurence; Kim, Yu Seun; Carmellini, Mario; Walker, Rowan; Zibari, Gazi; Pattison, James; Cornu‐artis, Catherine ; Wang, Zailong; Tedesco‐silva Jr, Helio (2013). "Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine." Clinical Transplantation 27(2): 217-226. <http://hdl.handle.net/2027.42/97483> | en_US |
dc.identifier.issn | 0902-0063 | en_US |
dc.identifier.issn | 1399-0012 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/97483 | |
dc.description.abstract | Background The association between clinical events and everolimus exposure in patients receiving reduced‐exposure calcineurin inhibitor therapy is poorly explored. Methods In a pre‐planned, descriptive analysis of data from a randomized controlled trial, events were correlated with everolimus trough concentrations in 556 newly transplanted kidney transplant patients receiving everolimus with reduced‐exposure cyclosporine ( C s A ) and steroids. Influence of everolimus exposure on clinical events was stratified according to predefined time‐normalized concentrations. Results The incidence of treated biopsy‐proven acute rejection and graft loss at month 12 was highest in patients with everolimus <3 ng/mL (36.4% and 28.6%, respectively, vs. 9.1–15.3% and 0.9–5.0% with higher concentration ranges). A higher mortality rate was observed in patients with an everolimus trough concentration ≥12 ng/mL (10.0% vs. 1.7–5.6% with lower concentration ranges). The lowest rates of renal dysfunction (defined as poor renal function [estimated GFR , serum creatinine] or proteinuria), wound healing events, peripheral edema, new‐onset diabetes mellitus, hypercholesterolemia and hypertriglyceridemia were generally observed with everolimus trough concentration in the range 3–8 ng/mL and C s A <100 ng/mL. Proteinuria occurred most frequently in patients with very low or very high everolimus trough concentrations. Conclusions These results support an exposure–response relationship between clinical events and everolimus trough concentrations in kidney transplant patients receiving reduced‐exposure C s A . | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Kidney Transplantation | en_US |
dc.subject.other | Efficacy | en_US |
dc.subject.other | Exposure | en_US |
dc.subject.other | Everolimus | en_US |
dc.subject.other | Therapeutic Drug Monitoring | en_US |
dc.title | Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.identifier.pmid | 23230975 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/97483/1/ctr12045.pdf | |
dc.identifier.doi | 10.1111/ctr.12045 | en_US |
dc.identifier.source | Clinical Transplantation | en_US |
dc.identifier.citedreference | Vitko S, Tedesco H, Eris J et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6‐month safety and efficacy results of two randomized studies. Am J Transplant 2004: 4: 626. | en_US |
dc.identifier.citedreference | Schuler W, Sedrani R, Cottens S et al. SDZ RAD, a new ramekin derivative: pharmacologic properties in vitro and in vivo. Transplantation 1997: 64: 36. | en_US |
dc.identifier.citedreference | Van Gurp E, Bustamante J, Franco A et al. Comparable renal function at 6 months with tacrolimus combined with fixed‐dose sirolimus or MMF: results of a randomized multicenter trial in renal transplantation. J Transplant 2010: 2010: pii 731426. | en_US |
dc.identifier.citedreference | Ciancio G, Burke GW, Gaynor JJ et al. A randomized long‐term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004: 77: 244. | en_US |
dc.identifier.citedreference | Albano L, Berthoux F, Moal MC et al. RAD A2420 Study Group. Incidence of delayed graft function and wound healing complications after deceased‐donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009: 88: 69. | en_US |
dc.identifier.citedreference | Tedesco Silva H Jr, Cibrik D, Johnston T et al. Everolimus plus reduced‐exposure CsA versus mycophenolic acid plus standard‐exposure CsA in renal‐transplant recipients. Am J Transplant 2010: 10: 1401. | en_US |
dc.identifier.citedreference | Chan L, Greenstein S, Hardy MA et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008: 85: 821. | en_US |
dc.identifier.citedreference | Schuurman J‐J, Cottens S, Fuchs S et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997: 64: 32. | en_US |
dc.identifier.citedreference | Salvadori M, Scolari MP, Bertoni E et al. Everolimus with very low‐exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 2009: 88: 1194. | en_US |
dc.identifier.citedreference | Chou T, Talalay P. Quantitative analysis of dose‐effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984: 22: 27. | en_US |
dc.identifier.citedreference | Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976: 16: 31. | en_US |
dc.identifier.citedreference | Nankivell BJ, Gruenewald SM, Allen R, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995: 59: 1683. | en_US |
dc.identifier.citedreference | Poggio ED, Wang X, Weinstein DM et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006: 6: 100. | en_US |
dc.identifier.citedreference | Chan L, Hartmann E, Cibrik D, Cooper M, Shaw LM. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation 2010: 90: 31. | en_US |
dc.identifier.citedreference | Lorber MI, Ponticelli C, Whelchel J et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12‐month exposure, efficacy, and safety data. Clin Transplant 2005: 19: 145. | en_US |
dc.identifier.citedreference | Kovarik JM, Kaplan B, Tedesco Silva H et al. Exposure‐response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 2002: 73: 920. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.